Skip to main content

Table 1 A summary of reported FA proteininhibitors and available structures or biochemical activities to facilitate drug development

From: Fanconi anemia pathway as a prospective target for cancer intervention

FA genes Protein structures Molecular activities Inhibitors References
FANCA 6LHS DNA binding, strand annealing and exchange HSP90i including withaferin A [66, 81, 128, 132]
FANCF 2IQC   Natural compounds from Wrightia religiosa [133, 134]
FANCL 3ZQS, 4CCG E3 ligase CU1, CU2 [34, 131, 135]
FANCM 4BXO, 4DAY, 4DRB, 4E45, 4M6W DNA binding MM2 peptide [136,137,138,139,140,141]
FANCT/UBE2T 1YH2, 4CCG, 5NGZ, 5OJJ E2 A few leads by fragment screening [34, 142,143,144]
FANCD2 3S4W DNA binding   [145]
FANCI 3S51 DNA binding Undisclosed [146, 147]
FANCP/SLX4 4M7C, 4UYI, 4ZOU DNA binding   [148]
FANCD1/BRCA2 1N0W, 3EU7 DNA binding Antisense oligonucleotide (ASO) [149,150,151]
FANCJ/BRIP1 1T15, 1T29, 3AL3 Helicase   [152,153,154]
FANCN/PALB2 2W18, 3EU7 DNA binding   [150]
FANCO/RAD51C   DNA binding   
FANCR/RAD51 1B22, 1N0W, 5H1B, 5H1C, 5JZC, 5NP7, 5NWL Strand exchange RI-1, RI-2, B02, CYT01A [149, 155,156,157,158,159,160,161]
FANCS/BRCA1 1JM7, 1JNX, 1N5O, 1OQA, 1T15, 1T29, 1T2U, 1T2V, 1Y98, 2ING, 3COJ, 3K0H, 3K0K, 3K15, 3K16, 3PXA, 3PXB, 3PXC, 3PXD, 3PXE, 4IFI, 4IGK, 4JLU, 4OFB, 4U4A, 4Y18, 4Y2G, 6G2I DNA binding   [152, 153, 162,163,164,165,166,167,168,169,170,171,172,173,174]
FANCV/REV7 3ABD, 3ABE, 3VU7, 4EXT, 4GK0, 4GK5, 5XPT, 5XPU, 6BC8, 6BCD, 6BI7 DNA binding REV7 specific compounds [175,176,177,178,179,180]
FANCQ/XPF 1Z00, 2A1J, 2AQ0, 2KN7, 2MUT DNA incision   [181,182,183,184,185]